Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: A randomized, double-blind placebo-controlled trial

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 10, 2006, Pages 1243-1247

  Tosti, Antonella ^a   Iorizzo, Matilde ^a   Botta, Gian Luca ^b   Milani, Massimo ^b,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b R and D Mipharm   (Italy)

^c NONE   (Italy)

Author keywords

Alopecia areata; Clobetasol; Randomized controlled trial

Indexed keywords

CLOBETASOL PROPIONATE; CORTICOTROPIN; HYDROCORTISONE; PLACEBO; VERSAFOAM;

ADULT; ALOPECIA AREATA; APPLICATION SITE FOLLICULITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ESTHETICS; FEMALE; HAIR GROWTH; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; ALOPECIA AREATA; CLOBETASOL; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLACEBOS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33750300542     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01781.x     Document Type: Article

References (19)

1. Stene JJ. Alopecia areata and treatment. Rev Med Brux 2004; 25: A282-A285.
2. Tosti A, Piraccini BM, Pazzaglia M. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. JAAD 2003; 49: 96-98.
3. Melian EB, Spencer CM, Jarvis B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol 2001; 2: 89-92.
4. Franz TJ, Parsell DA, Halualani RM. Betamethasone valerate foam 0.12%: A novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38: 628-632.
5. Franz TJ, Parsell DA, Myers JA, Hannigan JF. Clobetasol propionate foam 0.05%: A novel vehicle with enhanced delivery. Int J Dermatol 2000; 39: 535-538.
6. Housman T, Mellen B, Rapp S. Patients with psoriasis prefer solution and foam vehicles: A quantitative assessment of vehicle preference. Cutis 2002; 70: 327-332.
7. Charuwichitratana S. Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol 2000: 136.
8. Norris D. Alopecia areata: Current state of knowledge. J Am Acad Dermatol 2004; 51: S16-S17.
9. McDonagh AJ, Messenger Ag. The pathogenesis of alopecia areata. Dermatol Clinics 1996; 14: 661-670.
10. Alexis AF, Dudda-Subramanya R, Sinha AA. Alopecia areata: Autoimmune basis of hair loss. Eur J Dermatol 2004; 14: 364-370.
11. La Placa M, Vitone F, Bianchi T et al. Serum antibodies against human intracisternal A-type particle (HIAP) endogenous retrovirus in alopecia areata patients: A hallmark of autoimmune disease? J Invest Dermatol 2004; 123: 407-409.
12. Firooz A, Bouzari N, Mojtahed F et al. Topical immunotherapy with diphencyprone in the treatment of extensive and/or long-lasting alopecia areata. J Eur Acad Dermatol Venereol 2005; 19: 393-394.
13. Mancuso G, Balducci A, Casadio C et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: A multicenter, prospective, randomized, controlled, investigator-blinded trial. J Dermatol 2003; 42: 572-575.
14. Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 2005; 52: 287-290.
15. Olsen EA, Hordinsky MK, Price VH et al. Alopecia areata investigational assessment guidelines -part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004; 51: 440-447.
16. Fiedler VC. Alopecia areata. A review of therapy, efficacy, safety, and mechanism. Arch Dermatol 1992; 128: 1519-1529.
17. MacDonald Hull SP. Guidelines for the management of alopecia areata. Br J Dermatol 2003; 149: 692-699.
18. Stoughton RB, Cornell RC. Review of super-potent topical corticosteroid. Sem Dermatol 1987; 6: 72-76.
19. Skroza N, Innocenzi D. The thermophobic foams: Pharmacokinetic properties and clinical efficacy data. J Invest Dermatol 2004; 123: A87-A97.